Prothena data somewhat misunderstood by investors, says RBC Capital RBC Capital believes the pullback in Prothena's stock reflected some misunderstanding of data on the company's NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction. The firm believes that the data indicates that the drug is having a real impact. It keeps a $52 price target and Outperform rating on the stock.
UBS to hold a conference Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 18 at 8 am; not all company presentations may be webcasted. Webcast Link